Just a few years since pioneering a Covid-19 vaccine, Moderna faces a hostile political environment and a looming patent ...

The Trump administration’s decision to cut funding for Gavi, as part of a broader reduction in foreign aid, may have ...

Avidity Biosciences, Inc.'s innovative AOC platform and promising clinical programs make it a high-risk, high-reward ...

Sanofi will commence a Phase I/II trial with its vaccine candidate in the next few days to start generating immunogenicity ...